(Q37035703)

17 August 2017

1 reference

title

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy (English)

1 reference

17 August 2017

Chapman JR

1

1 reference

17 August 2017

Valantine H

2

1 reference

17 August 2017

Albanell J

3

1 reference

17 August 2017

Arns WA

4

1 reference

17 August 2017

Campistol JM

5

1 reference

17 August 2017

Eisen H

6

1 reference

17 August 2017

Frigerio M

7

1 reference

17 August 2017

Lehmkuhl H

8

1 reference

17 August 2017

Marcen R

9

1 reference

17 August 2017

Morris R

10

1 reference

17 August 2017

Nashan B

11

1 reference

17 August 2017

Pascual J

12

1 reference

17 August 2017

Pohanka E

13

1 reference

17 August 2017

Segovia J

14

1 reference

17 August 2017

Zuckermann A

15

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Transplantation Proceedings

17 August 2017

published in

1 reference

17 August 2017

volume

39

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

2937-2950

1 reference

Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report--2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Causes of death after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Chronic renal allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Improved long-term outcomes after renal transplantation associated with blood pressure control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cancer after kidney transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Lymphomas after solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus: its role in nephrology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Rapamycin for immunosuppression in organ allografting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Therapeutic potential of target of rapamycin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Population pharmacokinetics of sirolimus in kidney transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

SDZ RAD inhibits cold ischemia-induced vascular remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Impact of intravascular ultrasound in understanding transplant coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Nonhuman Primate Recipients of Orthotopic Aortic Allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Treatment of allograft vasculopathy in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Strategies to improve long-term outcomes after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Chronic allograft nephropathy: An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Assessing long-term nephron loss: is it time to kick the CAN grading system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Evolution of the renal function is a better predictor of long-term survival than serum creatinine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

'Old-for-old'--new strategies for renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Expanding the donor pool to increase renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

The impact of donor age on the results of renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Relationship of recipient age and development of chronic allograft failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Recipient age as an independent risk factor for chronic renal allograft failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Infectious disease complications of renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

The natural course of cytomegalovirus infection and disease in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Single-stage treatment of sternal wound complications in heart transplant recipients in whom pectoralis major myocutaneous advancement flaps were used

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Mediastinitis in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Uneventful thoracic healing with everolimus after aortic valve replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Risk factors of ischemic heart disease after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Hyperlipidemia and cardiovascular disease after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Studies on structural changes of the carotid arteries and the heart in asymptomatic renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Predicting coronary heart disease in renal transplant recipients: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Incidence and predictors of myocardial infarction after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

C-reactive protein and body mass index independently predict mortality in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Simvastatin initiated early after heart transplantation: 8-year prospective experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cancer incidence before and after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Post-transplant de novo malignancies in renal transplant recipients: the past and present

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Effects of Cyclosporine A on Experimental Hepatic Metastases of Mouse Colon-26 Tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Cardiovascular risk factors in renal transplantation--current controversies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.09.008

10.1016/J.TRANSPROCEED.2007.09.008

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference